Conor Medsystems
10
0
0
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
60.0%
6 terminated/withdrawn out of 10 trials
40.0%
-46.5% vs industry average
70%
7 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
A Randomized, Multi-Center Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent Systems (GENESIS)
Role: collaborator
Comparison of the Conor Sirolimus-eluting Coronary Stent to the Taxus Liberte Paclitaxel-eluting Coronary Stent in the Treatment of Coronary Artery Lesions
Role: collaborator
Conor Cobalt Chromium Reservoir Based Stent With Sirolimus Elution in Native Coronary Artery Lesions
Role: collaborator
Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)
Role: collaborator
The European Cobalt STent With Antiproliferative for Restenosis Trial (EuroSTAR Trial)
Role: collaborator
Prospective, Multi-Center, Random. Study of CoStar Paclitaxel-Eluting Coronary Stent(Direct Stenting vs. Pre-Dilatation)
Role: lead
CoStar Catheter System Evaluation
Role: lead
Multi-Center Clinical Trial: Evaluation of Effectiveness and Safety
Role: lead
CoStar™ Paclitaxel-Eluting Coronary Stent Catheter System Evaluation
Role: lead
Reduced Anti-Platelet Therapy With Pimecrolimus Drug Eluting Stent (RAPID)
Role: lead
All 10 trials loaded